Why the study?
Does intravenous mexiletine alter the electrophysiological properties of the heart in subjects without cardiovascular disease?
Population
10 subjects with no evidence of cardiovascular disease
Design
Other
Authors
Loading...
May warrant caution in conduction disease patients; leaves open effects in diseased hearts.
Does intravenous mexiletine alter the electrophysiological properties of the heart in subjects without cardiovascular disease?
Intravenous mexiletine significantly prolongs distal atrio-ventricular conduction in healthy subjects, highlighting the need for caution in patients with underlying conduction disease.
Harper et al. (1977) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: